BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 25988862)

  • 1. Novel CFI mutation in a patient with leukocytoclastic vasculitis may redefine the clinical spectrum of Complement Factor I deficiency.
    Bay JT; Katzenstein TL; Kofoed K; Patel D; Skjoedt MO; Garred P; Schejbel L
    Clin Immunol; 2015 Oct; 160(2):315-8. PubMed ID: 25988862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CNS Inflammation as the First Sign of Complement Factor I Deficiency: A Severe Myelitis Treated With Intense Immunotherapy and Eculizumab.
    Massey V; Nguyen CE; François T; De Bruycker JJ; Bonnefoy A; Lapeyraque AL; Decaluwe H
    Neurol Neuroimmunol Neuroinflamm; 2024 Mar; 11(2):e200191. PubMed ID: 38134378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement System Part II: Role in Immunity.
    Merle NS; Noe R; Halbwachs-Mecarelli L; Fremeaux-Bacchi V; Roumenina LT
    Front Immunol; 2015; 6():257. PubMed ID: 26074922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement Regulates Nutrient Influx and Metabolic Reprogramming during Th1 Cell Responses.
    Kolev M; Dimeloe S; Le Friec G; Navarini A; Arbore G; Povoleri GA; Fischer M; Belle R; Loeliger J; Develioglu L; Bantug GR; Watson J; Couzi L; Afzali B; Lavender P; Hess C; Kemper C
    Immunity; 2015 Jun; 42(6):1033-47. PubMed ID: 26084023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complementing T Cells' Functions: Bringing in Metabolism Matters.
    Boothby MR; Raybuck AL; Cho SH
    Immunity; 2015 Jun; 42(6):977-9. PubMed ID: 26084014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complement System Part I - Molecular Mechanisms of Activation and Regulation.
    Merle NS; Church SE; Fremeaux-Bacchi V; Roumenina LT
    Front Immunol; 2015; 6():262. PubMed ID: 26082779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunity.
    Wu MA; Castelli R
    Clin Chem Lab Med; 2016 Feb; 54(2):207-14. PubMed ID: 26068904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C5a alters blood-brain barrier integrity in a human in vitro model of systemic lupus erythematosus.
    Mahajan SD; Parikh NU; Woodruff TM; Jarvis JN; Lopez M; Hennon T; Cunningham P; Quigg RJ; Schwartz SA; Alexander JJ
    Immunology; 2015 Sep; 146(1):130-43. PubMed ID: 26059553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. European Union funded project on the development of a whole complement deficiency screening ELISA-A story of success and an exceptional manager: Mohamed R. Daha.
    Würzner R; Tedesco F; Garred P; Mollnes TE; Truedsson L; Turner MW; Sommarin Y; Wieslander J; Sim RB
    Mol Immunol; 2015 Nov; 68(1):63-6. PubMed ID: 26006049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement genetics and susceptibility to inflammatory disease. Lessons from genotype-phenotype correlations.
    de Córdoba SR
    Immunobiology; 2016 Jun; 221(6):709-14. PubMed ID: 26004345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complement Component 5 Mediates Development of Fibrosis, via Activation of Stellate Cells, in 2 Mouse Models of Chronic Pancreatitis.
    Sendler M; Beyer G; Mahajan UM; Kauschke V; Maertin S; Schurmann C; Homuth G; Völker U; Völzke H; Halangk W; Wartmann T; Weiss FU; Hegyi P; Lerch MM; Mayerle J
    Gastroenterology; 2015 Sep; 149(3):765-76.e10. PubMed ID: 26001927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paradoxical roles of C1q and C3 in autoimmunity.
    Scott D; Botto M
    Immunobiology; 2016 Jun; 221(6):719-25. PubMed ID: 26001732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma complement factor H is associated with disease activity of patients with ANCA-associated vasculitis.
    Chen SF; Wang FM; Li ZY; Yu F; Zhao MH; Chen M
    Arthritis Res Ther; 2015 May; 17(1):129. PubMed ID: 25994214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement factor I deficiency: A potentially treatable cause of fulminant cerebral inflammation.
    Altmann T; Torvell M; Owens S; Mitra D; Sheerin NS; Morgan BP; Kavanagh D; Forsyth R
    Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32098865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement Factor I Gene Variant as a Treatable Cause of Recurrent Aseptic Neutrophilic Meningitis: A Case Report.
    Rolfes M; Harroud A; Zorn KC; Tubati A; Omura C; Kurtz K; Matloubian M; Berger A; Chiu CY; Wilson MR; Ramachandran PS
    Neurol Neuroimmunol Neuroinflamm; 2023 Sep; 10(5):. PubMed ID: 37339889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel missense mutation in complement factor I predisposes patients to atypical hemolytic uremic syndrome: a case report.
    Wei X; Li J; Zhan X; Tu L; Huang H; Wang Y
    J Med Case Rep; 2022 Mar; 16(1):101. PubMed ID: 35241161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Classical and Non-classical Presentations of Complement Factor I Deficiency: Two Contrasting Cases Diagnosed via Genetic and Genomic Methods.
    Shields AM; Pagnamenta AT; Pollard AJ; ; Taylor JC; Allroggen H; Patel SY
    Front Immunol; 2019; 10():1150. PubMed ID: 31231365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous Vasculitis and Recurrent Infection Caused by Deficiency in Complement Factor I.
    Nanthapisal S; Eleftheriou D; Gilmour K; Leone V; Ramnath R; Omoyinmi E; Hong Y; Klein N; Brogan PA
    Front Immunol; 2018; 9():735. PubMed ID: 29696024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Versus Late Diagnosis of Complement Factor I Deficiency: Clinical Consequences Illustrated in Two Families with Novel Homozygous CFI Mutations.
    Franco-Jarava C; Álvarez de la Campa E; Solanich X; Morandeira-Rego F; Mas-Bosch V; García-Prat M; de la Cruz X; Martín-Nalda A; Soler-Palacín P; Hernández-González M; Colobran R
    J Clin Immunol; 2017 Nov; 37(8):781-789. PubMed ID: 28942469
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.